Form 6-K XTL BIOPHARMACEUTICALS For: Sep 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St futures dip as tech stocks take a breather
- Oil steadies as Middle East crude exports rise and G7 to release stocks
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
XTL Biopharma (XTLB) Reports Q2 Loss of $0.002/Share
September 27, 2016 8:33 AM EDTXTL Biopharma (NASDAQ: XTLB) reported Q2 EPS of $-0.002, versus $-0.001 reported last year.
For earnings history and earnings-related data on XTL Biopharma (XTLB) click here.
... More